FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Derek Maetzold, president and chief executive officer, and Frank Stokes, chief financial officer, are scheduled to present a company overview at Baird’s 2022 Global Healthcare Conference on Tuesday, Sept. 13, 2022, at 2:00 p.m. Eastern time.
A live audio webcast of the Company’s presentation will be available on Castle Biosciences’ website at https://ir.castlebiosciences.com/events-presentations/default.aspx. A replay of the webcast will be available for 90 days following the conclusion of the live broadcast.
Castle will also be available for one-on-one investor meetings during the 6th Annual Lake Street Best Ideas Growth (BIG6) Conference on Sept. 14, 2022. Meetings may be requested exclusively through Lake Street Capital Markets.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of Castle Biosciences, Inc.
